Role of the Circulating Procoagulants Microparticles in the Hypercoagulability of MNP Ph1-

Role of the Circulating Procoagulants Microparticles in the Hypercoagulability of Chronic Philadelphia Negative Myeloproliferative Neoplasms

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02862366

Acronym

MICROP-SMP

Enrollment

128

Registered

2016-08-11

Start date

2010-10-31

Completion date

2016-01-25

Last updated

2018-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myeloproliferative Neoplasm

Keywords

myeloproliferative neoplasms, Circulating Procoagulants Microparticles

Brief summary

Patients with myeloproliferative neoplasms Philadelphia chromosome negative (MPNsPh1-) such as Essential thrombocytosis (ET), Polycythemia vera (PV) and Primary Myelofibrosis (PMF) have a higher risk of arterial or deep-vein thrombosis. This is responsible for a significant increase in mortality (up to 31% of increase in thrombosis risk in ET). Cellular inflation and blood hyperviscosity, resulting from these diseases, fail to account for these thromboses, as more than 50% of thrombotic complications happen under adapted antineoplastic drug treatment. These last years, cellular microparticles (MPs) have been shown to play a major role in thrombogenesis. MPs are generated by apoptosis or the activation of malignant cells, platelets, endothelial cells or monocytes. They are fragments of plasma membrane, smaller than 1 µm, rich in phosphatidylserine, which can express the tissue factor and serve as support for the coagulation factors. Increase in the plasma concentration of procoagulant platelet microparticles has been demonstrated in other thrombotic diseases (acute coronary syndrome, disseminated intravascular coagulation DIC, etc.). The working hypothesis is that platelet microparticles are involved in the hypercoagulability of MPNs patients.

Interventions

OTHERBlood sampling

Blood sampling every 6 month following the routine calendar of visit

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

for MNPs patients: * Age \> 18 * Establish MNPs Phi- diagnosis (ET, PV, MFP) * Consent to participate Inclusion Criteria for healthy volunteers: * Healthy volunteers matched in age, sex with the MNPs patients, with a normal complete blood and platelet count * No personal thromboembolic history * No known thromboembolic risk factor : thrombophilia, cancers, and other disease associated with a thrombotic risk (Atrial fibrillation, etc.) * Not pregnant * Non smoker * For women, no hormonal contraceptives

Exclusion criteria

for MNPs patients: * Pregnancy * Patient unable to give consent

Design outcomes

Primary

Measure	Time frame
Comparison of the average number of microparticles detected by flow cytometry in all subgroup	Baseline

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026